Molecular Insight Pharmaceuticals Overview
- Founded
-
1998
- Status
-
Acquired/Merged
- Employees
-
71
- Latest Deal Type
-
M&A
- Financing Rounds
-
6
Molecular Insight Pharmaceuticals General Information
Description
Developer of small-molecule chemistry platform to significantly impact the care of men with prostate cancer. The company offers clinical stage specialty that are focused on critical unmet diagnostic and therapeutic needs of the prostate cancer patient.
Contact Information
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Parent Company
Primary Office
- 160 Second Street
- Cambridge, MA 02142
- United States
+1 (617) 000-0000
Molecular Insight Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Molecular Insight Pharmaceuticals Patents
Molecular Insight Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-9956305-B2 | Organ protection in psma-targeted radionuclide therapy of prostate cancer | Active | 08-Sep-2014 | 00000000000 | 00 |
| EP-3193914-A1 | Organ protection in psma-targeted radionuclide therapy of prostate cancer | Granted | 08-Sep-2014 | 00000000000 | |
| EP-3193914-B1 | Organ protection in psma-targeted radionuclide therapy of prostate cancer | Active | 08-Sep-2014 | 00000000000 | |
| US-20160067361-A1 | Organ protection in psma-targeted radionuclide therapy of prostate cancer | Granted | 08-Sep-2014 | 00000000000 | 0 |
| US-20200254120-A1 | Organ protection in psma-targeted radionuclide therapy of prostate cancer | Granted | 08-Sep-2014 | A61K51/0497 |
Molecular Insight Pharmaceuticals Executive Team (10)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Nelson Stacks | Chief Executive Officer & Director | ||
| John Babich Ph.D | Interim Chief Executive Officer & Chairman of the Board | ||
| Barry Frankel | Director |
Molecular Insight Pharmaceuticals Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 000000 | Self | Board Member | 000 0000 |
| 0000 000000 00.0 | Molecular Insight Pharmaceuticals | Interim Chief Executive Officer & Chairman of the Board | 000 0000 |
| 000000 000000000 00 | Self | Board Member | 000 0000 |
Molecular Insight Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Molecular Insight Pharmaceuticals Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|